Document:

Exhibit 10.1

                    EXECUTIVE EMPLOYMENT AGREEMENT AMENDMENT

         THIS EMPLOYMENT AGREEMENT AMENDMENT ("AGREEMENT"), is made and entered
into by and between Sharps Compliance Corp., having its principle office at 9350
Kirby Drive, Suite 300, Houston, TX 77054 (hereinafter referred to as the
"Company"), and David P. Tusa (hereinafter referred to as the "Executive").

                                   WITNESSETH

For and in consideration of the mutual promises and covenants herein contained,
and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Company and Executive agree to amend the
Executive's original executive employment agreement, dated July 14, 2003 and
amended on October 1, 2004 (effective June 21, 2004), as follows:

         The Base Salary referred to in Article 1.3.1 (as amended) of $8,653.85
per pay period is hereby changed to $9,615.38.

         Notwithstanding anything to the contrary, Executive is entitled to no
less than twelve (12) month's severance-related pay and benefits under Article 2
of the Agreement.

IN WITNESS WHEREOF, the parties have executed this Agreement the day and year
first written below with the amended provisions noted above being effective
August 19, 2005.

EXECUTIVE:

/s/ David P. Tusa
-----------------
Executive

Date: August 19, 2005

COMPANY:

/s/ Burton J. Kunik
-------------------
Name:             Burton J. Kunik

Title:            Chairman & Chief Executive Officer

Date:    August 19, 2005
         ---------------EXHIBIT 4.1

                         COMMON STOCK PURCHASE AGREEMENT

  THIS COMMON STOCK PURCHASE AGREEMENT ("Agreement") is made and entered into as
  of August 17, 2005 (the "Effective Date"), by and between GERON CORPORATION, a
  Delaware corporation having its principal place of business at 230
  Constitution Drive, Menlo Park, California 94025 ("Geron"), and TRANSGENOMIC,
  INC., a Delaware corporation having its principal place of business at 12325
  Emmet Street, Omaha, Nebraska 68164 ("Transgenomic").

        A.        Geron and Transgenomic are the parties to that certain Supply
                  Agreement dated as of June 15, 2002 (the "Supply Agreement"),
                  and related Addendum Agreements ("Addendum Agreement") under
                  which Geron has agreed to purchase certain products from
                  Transgenomic and Transgenomic has agreed to supply such
                  products to Geron on the terms set forth therein.

        B.        Pursuant to Addendum Agreement No. 9 dated as of April 6,
                  2005, Addendum Agreement No. 10 dated as of April 6, 2005, and
                  the Second Amendment to Addendum Agreement No. 10 dated as of
                  August 17, 2005 (collectively, the foregoing are referred to
                  herein as the "Addenda"), Geron may pay the purchase price of
                  products by delivery of shares of Geron's Common Stock (the
                  "Shares").

THE PARTIES AGREE AS FOLLOWS:

1.    ISSUANCE OF SHARES; ADJUSTMENTS.
      1.1     As payment of (a) the Second Installment specified in Addendum
              Agreement No. 9 and Addendum Agreement No. 10 and (b) the
              Installment specified in the Second Amendment to Addendum
              Agreement No. 10, Geron will issue and deliver certificates for
              151,550 shares. Upon issuance and delivery of the certificate(s)
              for the Shares, all Shares shall be duly authorized and validly
              issued and represent fully paid shares of Geron's Common Stock.

2.    CLOSING; DELIVERY.

      2.1     The consummation of the transaction contemplated by this Agreement
              (a "Closing") shall be held at such time and place as is mutually
              agreed upon between the parties, but in any event no later than
              three (3) business days after the Effective Date of this Agreement
              (the "Closing Date"). At the Closing, Geron shall deliver to
              Transgenomic one or more certificates representing all of the
              Shares, which Shares shall be issued in the name of Transgenomic
              or its designee and in such denominations as Transgenomic shall
              specify.

      2.2     Geron's obligations to issue and deliver the stock certificate(s)
              representing the Shares to Transgenomic at the Closing shall be
              subject to the following conditions, which may be waived by Geron:

              2.2.1   the covenants and obligations that Transgenomic is
                      required to perform or to comply with pursuant to this
                      Agreement, at or prior to the Closing, must have been duly
                      performed and complied with in all material respects; and

              2.2.2   the representations and warranties made by Transgenomic
                      herein shall be true and correct in all material respects
                      as of the Closing Date.

      2.3     Transgenomic's obligation to accept delivery of the stock
              certificate(s) representing the Shares at the Closing shall be
              subject to the following conditions, any one or more of which may
              be waived by Transgenomic:

                                       1

<PAGE>

              2.3.1   the covenants and obligations that Geron is required to
                      perform or to comply with pursuant to this Agreement and
                      under the Common Stock Purchase Agreements specified in
                      Addendum Agreement Nos. 9 and 10 between the parties
                      hereto dated April 6, 2005, at or prior to the Closing,
                      must have been duly performed and complied with in all
                      material respects;

              2.3.2   Geron shall have available under its Certificate of
                      Incorporation sufficient authorized shares of Common Stock
                      to issue the Shares to Transgenomic; and

              2.3.3   the representation and warranties made by the Geron herein
                      shall be true and correct in all material respects as of
                      any Closing Date.

3.    RESTRICTIONS ON RESALE OF SHARES.

      3.1     Legends. Transgenomic understands and acknowledges that the Shares
              are not registered under the Securities Act of 1933 (the "Act"),
              and that under the Act and other applicable laws Transgenomic may
              be required to hold such Shares for an indefinite period of time.
              Each stock certificate representing Shares shall bear the
              following legends:

              "THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER
              THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). ANY TRANSFER
              OF SUCH SECURITIES SHALL BE INVALID UNLESS A REGISTRATION
              STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH TRANSFER OR, IN
              THE OPINION OF COUNSEL REASONABLY ACCEPTABLE TO GERON, SUCH
              REGISTRATION IS UNNECESSARY FOR SUCH TRANSFER TO COMPLY WITH THE
              ACT. THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO THE TERMS OF
              THE COMMON STOCK PURCHASE AGREEMENT, DATED AUGUST 17, 2005. A COPY
              OF THE AGREEMENT CAN BE OBTAINED FROM THE SECRETARY OF GERON."

      3.2     Limits on Sales. Transgenomic agrees that if it decides to resell
              some or all of the Shares, it will do so only in an appropriate
              manner based upon whether the shares are registered or
              unregistered, i.e., on the Nasdaq National Market or in a Rule
              144A compliant transaction. Subject to the foregoing restrictions,
              Transgenomic may sell or resell the Shares in any lot size, or at
              any volume, desired by Transgenomic.

4.    REGISTRATION RIGHTS

      4.1     Geron agrees to make commercially reasonable best efforts to file
              with the Securities and Exchange Commission (the "Commission")
              within five (5) business days after the Closing Date, a
              registration statement under the Act (the "Registration
              Statement"), on Form S-3 or other appropriate form, so as to
              permit a non-underwritten public offering and resale of the Shares
              under the Act by Transgenomic. Geron agrees to diligently pursue
              making the Registration Statement effective. Geron will notify
              Transgenomic of the effectiveness of the Registration Statement
              within one (1) business day of receiving notice from the
              Commission.

      4.2     Geron will maintain the Registration Statement and any
              post-effective amendment thereto filed under this Section 4
              effective under the Act until the earliest of (i) the date that
              none of the Shares covered by such Registration Statement are
              issued and outstanding, (ii) the date that all of the Shares have
              been sold pursuant to such Registration Statement, (iii) the date
              Transgenomic receives an opinion of counsel to Geron, which
              counsel shall be reasonably acceptable to Transgenomic, that the
              Shares may be sold under the provisions of Rule 144 without
              limitation as to volume, (iv) the date that all Shares have been
              otherwise transferred to persons who may trade such shares without
              restriction under the Act, and Geron has delivered a new
              certificate or other evidence of ownership for such securities not
              bearing a restrictive legend, or (v) the date all Shares may be
              sold at any time, without volume or manner of sale limitations
              pursuant to Rule 144(k) or any similar provision then in effect
              under the Act in the opinion of counsel to Geron, which counsel
              shall be reasonably acceptable to Transgenomic.

                                       2

<PAGE>

      4.3     Geron, at its expense, shall furnish to Transgenomic with respect
              to the Shares registered under the Registration Statement such
              reasonable number of copies of the Registration Statement,
              prospectuses and preliminary prospectuses in conformity with the
              requirements of the Act and such other documents as Transgenomic
              may reasonably request, in order to facilitate the public sale or
              other disposition of all or any of the Shares by Transgenomic,
              provided, however, that the obligation of Geron to deliver copies
              of prospectuses or preliminary prospectuses to Transgenomic shall
              be subject to the receipt by Geron of reasonable assurances from
              Transgenomic that Transgenomic will comply with the applicable
              provisions of the Act and of such other securities or blue sky
              laws as may be applicable in connection with any use of such
              prospectuses or preliminary prospectuses.

      4.4     All fees, disbursements and out-of-pocket expenses and costs
              incurred by Geron in connection with the preparation and filing of
              the Registration Statement under Section 4.1 and in complying with
              applicable securities and Blue Sky laws (including, without
              limitation, all attorneys' fees of Geron) shall be borne by Geron.
              Transgenomic shall bear the cost of fees and expenses of
              Transgenomic's counsel.

      4.5     Geron will advise Transgenomic promptly after it shall receive
              notice or obtain knowledge of the issuance of any stop order by
              the Commission delaying or suspending the effectiveness of the
              Registration Statement or of the initiation of any proceeding for
              that purpose, and Geron will use its commercially reasonable
              efforts to prevent the issuance of any stop order or to obtain its
              withdrawal at the earliest possible moment if such stop order
              should be issued.

      4.6     With a view to making available to Transgenomic the benefits of
              Rule 144 (or its successor rule) and any other rule or regulation
              of the Commission that may at the time permit Transgenomic to sell
              the Shares to the public without registration, Geron covenants and
              agrees to: (i) make and keep public information available, as
              those terms are understood and defined in Rule 144, until the
              earliest of (A) such date as all of the Shares may be resold
              pursuant to Rule 144(k) or any other rule of similar effect or (B)
              such date as all of the Shares shall have been resold; and (ii)
              file with the Commission in a timely manner all reports and other
              documents required of Geron under the Act and under the Exchange
              Act of 1934, as amended.

      4.7     Transgenomic will cooperate with Geron in all respects in
              connection with this Agreement, including timely supplying all
              information reasonably requested by Geron (which shall include all
              information regarding Transgenomic and proposed manner of sale of
              the Shares required to be disclosed in any Registration Statement)
              and executing and returning all documents reasonably requested in
              connection with the registration and sale of the Shares and
              entering into and performing their obligations under any
              underwriting agreement, if the offering is an underwritten
              offering, in usual and customary form, with the managing
              underwriter or underwriters of such underwritten offering. Nothing
              in this Agreement shall obligate Transgenomic to consent to be
              named as an underwriter in any Registration Statement.

5.    INDEMNIFICATION.

      5.1     Geron agrees to indemnify and hold harmless Transgenomic (and each
              person, if any, who controls Transgenomic within the meaning of
              Section 15 of the Act, and each officer and director of
              Transgenomic) against any and all losses, claims, damages or
              liabilities (or actions or proceedings in respect thereof), joint
              or several, directly or indirectly based upon or arising out of
              (i) any untrue statement or alleged untrue statement of any
              material fact contained in the Registration Statement, any
              preliminary prospectus, final prospectus or summary prospectus
              contained therein or used in connection with the offering of the
              Shares, or any amendment or supplement thereto, or

                                       3

<PAGE>

              (ii) any omission or alleged omission to state a material fact
              required to be stated therein or necessary to make the statements
              therein not misleading; and Geron will reimburse each such
              indemnified party for any legal or any other expenses reasonably
              incurred by them in connection with investigating, preparing,
              pursuing or defending any such loss, claim, damage, liability,
              action or proceeding, except insofar as any such loss, claim,
              damage, liability, action, proceeding or expense (A) arises out of
              or is based upon an untrue statement or alleged untrue statement
              or omission or alleged omission made in the Registration
              Statement, any such preliminary prospectus, final prospectus,
              summary prospectus, amendment or supplement in reliance upon and
              in conformity with written information furnished to Geron by
              Transgenomic or such other person expressly for use in the
              preparation thereof, (B) the failure of Transgenomic to comply
              with its covenants and agreements contained in Sections 7.1 or
              7.5.2 hereof or (C) any misstatement or omission in any prospectus
              that is corrected in any subsequent prospectus that was delivered
              to Transgenomic prior to the pertinent sale or sales by
              Transgenomic. Such indemnity shall remain in full force and
              effect, regardless of any investigation made by such indemnified
              party and shall survive the transfer of the Shares by
              Transgenomic.

      5.2     Transgenomic agrees to indemnify and hold harmless Geron (and each
              person, if any, who controls Geron within the meaning of Section
              15 of the Act, each officer of Geron who signs the Registration
              Statement and each director of Geron) from and against losses,
              claims, damages or liabilities (or actions or proceedings in
              respect thereof), joint or several, directly or indirectly based
              upon or arising out of, (i) any failure of Transgenomic to comply
              with the covenants and agreements contained in Sections 7.1 and
              7.5.2 hereof or (ii) any untrue statement of a material fact
              contained in the Registration Statement or any omission of a
              material fact required to be stated in the Registration Statement
              or necessary in order to make the statements in the Registration
              Statement not misleading if such untrue statement or omission was
              made in reliance upon and in conformity with written information
              furnished to Geron by on behalf of Transgenomic specifically for
              use in preparation of the Registration Statement; provided,
              however, that Transgenomic shall not be liable in any such case
              for (A) any untrue statement or omission in the Registration
              Statement, prospectus, or other such document which statement is
              corrected by Transgenomic and delivered to Geron prior to the sale
              from which such loss occurred, (B) any untrue statement or
              omission in any prospectus which is corrected by Transgenomic in
              any subsequent prospectus, or supplement or amendment thereto, and
              delivered to Geron prior to the sale or sales from which a loss or
              liability arose, or (C) any failure by Geron to fulfill any of its
              obligations under Section 5.1 hereof.

      5.3     Promptly after receipt by any indemnified person of a notice of a
              claim or the beginning of any action in respect of which indemnity
              is to be sought against an indemnifying person pursuant to this
              Section 5, such indemnified person shall notify the indemnifying
              person in writing of such claim or of the commencement of such
              action, but the omission to so notify the indemnifying party will
              not relieve it from any liability which it may have to any
              indemnified party under this Section 5 (except to the extent that
              such omission materially and adversely affects the indemnifying
              party's ability to define such action) or from any liability
              otherwise than under this Section 5. Subject to the provisions
              hereinafter stated, in case any such action shall be brought
              against an indemnified person, the indemnifying person shall be
              entitled to participate therein, and, to the extent that it shall
              elect by written notice delivered to the indemnified party
              promptly after receiving the aforesaid notice from such
              indemnified party, shall be entitled to assume the defense
              thereof, with counsel reasonably satisfactory to such indemnified
              person.

                                       4

<PAGE>

              After notice from the indemnifying person to such indemnified
              person of its election to assume the defense thereof, such
              indemnifying person shall not be liable to such indemnified person
              for any legal expense subsequently incurred by such indemnified
              person in connection with the defense thereof, provided, however,
              that if there exists or shall exist a conflict of interest that
              would make inappropriate, in the reasonable opinion of counsel to
              the indemnified person, for the same counsel to represent both the
              indemnified person and such indemnifying person or any affiliate
              or associate thereof, the indemnified person shall be entitled to
              retain its own counsel at the expense of such indemnifying person;
              provided, however, that no indemnifying person shall be
              responsible for the fees and expenses of more than on separate
              counsel (together with appropriate local counsel) for all
              indemnified parties. In no event shall any indemnifying person be
              liable in respect to any amounts paid in settlement of any action
              unless the indemnifying person shall have approved the terms of
              such settlement. No indemnifying person shall, without the prior
              written consent of the indemnified person, effect any settlement
              of any pending or threatened proceeding in respect of which any
              indemnified person is or could have been a party and
              indemnification could have been sought hereunder by such
              indemnified person, unless such settlement includes an
              unconditional release of such indemnified person from all
              liability on claims that are the subject matter of such
              proceeding.

      5.4     The provisions of this Section 5 shall survive the termination
              of this Agreement.

6.    REPRESENTATIONS AND ACKNOWLEDGEMENT OF GERON.

       Geron hereby represents, warrants and covenants to Transgenomic as
       follow:

      6.1     Organization, Good Standing and Qualification. Geron is a
              corporation duly organized, validly existing and in good standing
              under the laws of the State of Delaware and has all requisite
              corporate power and authority to carry on its business as now
              conducted and as presently proposed to be conducted. Geron is duly
              qualified to transact business and is in good standing as a
              foreign corporation in each jurisdiction in which the failure to
              so qualify would have a material adverse effect on its business or
              properties.

      6.2     Authorization. All corporate action on the party of Company, its
              officers, directors and stockholders necessary for the
              authorization, execution and delivery of this Agreement, the
              performance of all obligations of Company hereunder and the
              authorization, issuance and delivery of the Shares has been taken
              or will be taken prior to the Closing, and this Agreement, when
              executed and delivered will constitute valid and legally binding
              obligations of Geron, enforceable against Geron in accordance with
              their terms, except as limited by applicable bankruptcy,
              insolvency, reorganization, moratorium, fraudulent conveyance and
              other laws of general application affecting enforcement of
              creditors' rights generally, as limited by laws relating to the
              availability of specific performance, injunctive relief or other
              equitable remedies.

      6.3     Valid Issuance of Common Stock. The Shares, when issued, sold and
              delivered in accordance with the terms hereof for the
              consideration expressed herein, will be duly and validly
              authorized and issued, fully paid and nonassessable and free of
              restrictions on transfer other than restrictions on transfer under
              this Agreement and applicable state and federal securities laws.

      6.4     Legal Proceedings and Orders. There is no action, suit, proceeding
              or investigation pending or threatened against Geron that
              questions the validity of this Agreement or the right of Geron to
              enter into this Agreement or to consummate this transactions
              contemplated hereby, nor is Geron aware of any basis for any of
              the forgoing. Geron is neither a party nor subject to the
              provisions of any order, writ, injunction, judgment or decree of
              any court or government agency or instrumentality that would
              affect the ability of Geron to enter into this Agreement or to
              consummate the transactions contemplated hereby.

7.    REPRESENTATIONS AND ACKNOWLEDGMENTS OF TRANSGENOMIC.

      Transgenomic hereby represents, warrants, acknowledges and agrees that:

                                       5

<PAGE>

      7.1     Investment. Transgenomic is acquiring the Shares for
              Transgenomic's own account, and not directly or indirectly for the
              account of any other person. Transgenomic is acquiring the Shares
              for investment and not with a view to distribution or resale
              thereof, except in compliance with the Act and any applicable
              state law regulating securities.

      7.2     Access to Information. Transgenomic has consulted with its own
              attorney, accountant, or investment advisor as Transgenomic has
              deemed advisable with respect to the investment and has determined
              its suitability for Transgenomic. Transgenomic has had the
              opportunity to ask questions of, and to receive answers from,
              appropriate executive officers of Geron with respect to the terms
              and conditions of the transactions contemplated hereby and with
              respect to the business, affairs, financial condition and results
              of operations of Geron. Transgenomic has had access to such
              financial and other information as is necessary in order for
              Transgenomic to make a fully informed decision as to investment in
              Geron, and has had the opportunity to obtain any additional
              information necessary to verify any of such information to which
              Transgenomic has had access. Transgenomic acknowledges that
              neither Geron nor any of its officers, directors, employees,
              agents, representatives, or advisors have made any representation
              or warranty other than those specifically expressed herein.

      7.3     Business and Financial Expertise. Transgenomic further represents
              and warrants that it has such business or financial expertise as
              to be able to evaluate its investment in Geron and purchase of the
              Shares.

      7.4     Speculative Investment. Transgenomic acknowledges that the
              investment in Geron represented by the Shares is highly
              speculative in nature and is subject to a high degree of risk of
              loss in whole or in part; the amount of such investment is within
              Transgenomic's risk capital means and is not so great in relation
              to Transgenomic's total financial resources as would jeopardize
              the personal financial needs of Transgenomic in the event such
              investment were lost in whole or in part.

      7.5     Unregistered Securities.  Transgenomic acknowledges that:

              7.5.1   Transgenomic must bear the economic risk of investment
                      for an indefinite period of time because the Shares
                      have not been registered under the Act and therefore
                      cannot and will not be sold unless they are
                      subsequently registered under the Act or an exemption
                      from such registration is available. Geron has made no
                      agreements, covenants or undertakings whatsoever to
                      register any of the Shares under the Act, except as
                      provided in Section 4 above. Geron has made no
                      representations, warranties or covenants whatsoever as
                      to whether any exemption from the Act, including,
                      without limitation, any exemption for limited sales in
                      routine brokers' transactions pursuant to Rule 144
                      under the Act, will become available and any such
                      exemption pursuant to Rule 144, if available at all,
                      will not be available unless: (i) a public trading
                      market then exists in Geron's common stock, (ii) Geron
                      has complied with the information requirements of Rule
                      144, and (iii) all other terms and conditions of Rule
                      144 have been satisfied.

              7.5.2   Transfer of the Shares has not been registered or
                      qualified under any applicable state law regulating
                      securities and, therefore, the Shares cannot and will not
                      be sold unless they are subsequently registered or
                      qualified under any such act or an exemption therefrom is
                      available. Geron has made no agreements, covenants or
                      undertakings whatsoever to register or qualify any of the
                      Shares under any such act. Geron has made no
                      representations, warranties or covenants whatsoever as to
                      whether any exemption from any such act will become
                      available.

              7.5.3   Transgenomic hereby certifies that it is an "Accredited
                      Investor" as that term is defined in Rule 501 under the
                      Act.

                                       6

<PAGE>

8.     TAX ADVICE. Transgenomic acknowledges that Transgenomic has not relied
       and will not rely upon Geron or Geron's counsel with respect to any tax
       consequences related to the ownership, purchase, or disposition of the
       Shares. Transgenomic assumes full responsibility for all such
       consequences and for the preparation and filing of all tax returns and
       elections which may or must be filed in connection with the Shares.

9.     NOTICES. Any notice or other communication required or permitted
       hereunder shall be in writing and shall be deemed to have been duly given
       on the date of delivery if delivered personally or by facsimile, or one
       day, not including Saturdays, Sundays, or national holidays, after
       sending if sent by national overnight delivery service, or five days, not
       including Saturdays, Sundays, or national holidays, after mailing if
       mailed by first class United States mail, certified or registered with
       return receipt requested, postage prepaid, and addressed as follows:

             To Geron at:                   Geron Corporation
                                            230 Constitution Drive
                                            Menlo Park, California  94025
                                            Attention: General Counsel
                                            Telephone:        (650) 473-7700
                                            Facsimile:        (650) 473-7750

             To Transgenomic at:            Transgenomic, Inc.
                                            12325 Emmet Street
                                            Omaha, Nebraska 68164
                                            Attention:  Law Department
                                            Telephone:        (402) 452-5400
                                            Facsimile:        (402) 452-5447

10.    BINDING EFFECT. This Agreement shall be binding upon the heirs, legal
       representatives and successors of Geron and of Transgenomic; provided,
       however, that Transgenomic may not assign any rights or obligations under
       this Agreement.

11.    GOVERNING LAW. This Agreement shall be governed by and construed in
       accordance with the laws of the State of California.

12.    INVALID PROVISIONS. In the event that any provision of this Agreement is
       found to be invalid or otherwise unenforceable by a court or other
       tribunal of competent jurisdiction, such invalidity or unenforceability
       shall not be construed as rendering any other provision contained herein
       invalid or unenforceable, and all such other provisions shall be given
       full force and effect to the same extent as though the invalid and
       unenforceable provision was not contained herein.

13.    COUNTERPARTS. This Agreement may be executed in any number of identical
       counterparts, each of which shall be deemed an original, but all of which
       together shall constitute one and the same instrument.

14.    AMENDMENTS. This Agreement or any provision hereof may be changed,
       waived, or terminated only by a statement in writing signed by the party
       against whom such change, waiver or termination is sought to be enforced.

15.    FUTURE COOPERATION. Each of the parties hereto agrees to cooperate at all
       times from and after the date hereof with respect to all of the matters
       described herein, and to execute such further assignments, releases,
       assumptions, amendments of the Agreement, notifications and other
       documents as may be reasonably requested for the purpose of giving effect
       to, or evidencing or giving notice of, the transactions contemplated by
       this Agreement.

                                       7

<PAGE>

16.    ENTIRE AGREEMENT. This Agreement, the Common Stock Purchase Agreements
       specified in Addendum Agreement Nos. 9 and 10 dated as of April 6, 2005,
       and the Supply Agreement, including Addendum Agreement No. 10 thereto,
       constitute the entire agreement of the parties pertaining to the Shares
       and supersede all prior and contemporaneous agreements, representations,
       and understandings of the parties with respect thereto.

       IN WITNESS WHEREOF, the parties hereto have executed this Common Stock
Purchase Agreement as of the date first above written.
                                     Geron Corporation

                                      /s/ David L. Greenwood
                                     -------------------------------------------
                                     By:      David L. Greenwood
                                     Title:   Executive Vice President and Chief
                                              Financial Officer

                                     Transgenomic, Inc.

                                      /s/ Michael Summers
                                     -------------------------------------------
                                     By:      Michael Summers
                                     Title:   Chief Executive Officer

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]